نوع مقاله : مقاله پژوهشی

نویسندگان

1 استادیار، بخش نورولوژی، دانشکده ی پزشکی، دانشگاه علوم پزشکی شیراز، شیراز، ایران

2 عضو مرکز تحقیقات نورولوژی بالینی، دانشگاه علوم پزشکی شیراز، شیراز، ایران

چکیده

مقدمه: میگرن بیماری نورولوژیک است که با سردردهای شدید همراه با حالت تهوع مشخص می‌شود. هدف از این مطالعه بررسی میزان افسردگی و ناتوانی در بیماران میگرنی درمان‌شده در مقایسه با بیماران درمان‌نشده است.
روش‌ها: مطالعه حاضر به‌صورت یک مطالعه مقطعی روی بیماران مبتلا به سردرد میگرنی که بر اساس معیارهای واجد شرایط مطالعه به مدت سه ماه از فروردین تا تیرماه 1396 به درمانگاه سرپایی امام رضا (ع) مراجعه کرده بودند، طراحی شد. بیماران واجد شرایط به دو گروه تقسیم شدند. یک گروه بیمارانی که درمان استاندارد میگرن را حداقل به مدت یک ماه دریافت کرده بودند و گروه دیگر بیمارانی بودند که درمان استاندارد میگرن را دریافت نکرده بودند و فقط برای کنترل درد از داروهای ضد درد استفاده می‌کردند. پس از معاینه دقیق، از شرکت‌کنندگان خواسته شد تا نسخه فارسی معتبر و قابل اعتمادBeck’s Depression Inventory ((BDI وMigraine Disability Assessment (MIDAS) را برای ارزیابی سطح افسردگی و ناتوانی پر کنند.
یافته‌ها: تعداد 283 بیمار مبتلا به سردرد میگرنی وارد مطالعه شدند. امتیاز MIDAS در گروه درمان‌شده (درمان دارویی استاندارد) به‌طور معنی‌داری کمتر از گروه درمان‌نشده بود (به ترتیب 2/3±1/7، 9/10±3/14، 001/0P=). میانگین امتیاز BDI در گروه درمان‌شده 6/4±6/9 و در گروه درمان‌نشده 9/10±3/14 بود (004/0=P).
نتیجه‌گیری: مشاهدات نهایی ما این است که افراد مبتلا به میگرن درمان‌نشده بیشتر از بیماران مبتلا به میگرن درمان‌شده افسردگی و اضطراب را دارند.
 

کلیدواژه‌ها

عنوان مقاله [English]

Comparison of the Level of Depression and Disability between the Treated and Untreated Migraineurs

نویسندگان [English]

  • Vahid Reza Ostovan 1
  • Seyed Amir Mohammad Mirghasemi 2

1 M.D., Assistant Professor, Department of Neurology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Member of Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

چکیده [English]

Introduction: Migraine is a neurologic problem characterized by severe headache and nausea. This study aimed to compare the level of depression and disability between treated and untreated migraineurs.
Methods: The present study was designed as a cross-sectional study conducted on patients with migraine headaches who were referred to the outpatient clinic of Emam Reza and selected through purposive sampling to participate in the study for three months from April to July in 2017. The eligible patients referred to our clinic were divided into two study groups. One group included the migraineurs who received the standard treatment for migraine for at least one month, whereas the migraineurs in the second group didn’t receive standard treatment while they received analgesic agents as pain killers. After an inclusive examination by a neurologist, the participants were asked to fill out the valid and reliable Persian versions of BDI and MIDAS to assess the level of depression and disability.
Result: Overall, the authors had a total of 283 patients with migraine headaches. We found that the MIDAS score in the treated group was significantly lower than the untreated group (7.1±3.2, 14.3±10.9, respectively, P=0.001). In addition, the mean BDI score in the treated group was 9.6±4.6, whereas it was 14.3±10.9 in the untreated group (P=0.004).
Conclusion: is the study showed that subjects with untreated migraine are more likely to report depression and anxiety than patients with treated migraine.

کلیدواژه‌ها [English]

  • Anxiety
  • Depression
  • Headache
  • Migraine
  1. Stovner L, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27(3):193-210.
  2. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA. 1992;267(1):64-9.
  3. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol. 1994;34(2):6-11.
  4. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.
  5. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4):973-89.
  6. Minen MT, Begasse De Dhaem O, Kroon Van Diest A, Powers S, Schwedt TJ, Lipton R, et al. Migraine and its psychiatric comorbidities. J Neurol Neurosurg Psychiatry. 2016;87(7):741-9.
  7. Baskin SM, Smitherman TA. Migraine and psychiatric disorders: comorbities, mechanisms, and clinical applications. Neurol Sci. 2009;30(1):61-5.
  8. Hamelsky SW, Lipton RB. Psychiatric comorbidity of migraine. Headache. 2006;46(9):1327-33.
  9. Wang SJ, Liu HC, Fuh JL, Liu CY, Wang PN, Lu SR. Comorbidity of headaches and depression in the elderly. Pain. 1999;82(3):239-43.
  10. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case–control study. Neurology. 2000;55(5):629-35.
  11. Merikangas KR, Angst J, Isler H. Migraine and psychopatology. Results of Zurich cohort study of young adults. Arch Gen Psychiatry. 1990;47(9):849-53.
  12. Breslau N, Schultz LR, Stewart WF, Lipton RB, Lucia VC, Welch KM. Headache and major depression: is the association specific to migraine? Neurology. 2000;54(2):308-13.
  13. Swartz KL, Pratt LA, Armenian HK, Lee LC, Eaton WW. Mental disorders and the incidence of migraine headache in a community sample. Arch Gen Psychiatry. 2000;57(10):945-50.
  14. Patel NV, Bigal ME, Koloner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology. 2004;63(8):1432-8.
  15. Fasmer OB, Oedegaard KJ. Clinical characteristics of patients with major affective disorders and comorbid migraine. World J Biol Psychiatry. 2001;2(3):149-55.
  16. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression. Neurology. 2003;60(8):1308-12.
  17. Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts:  an   epidemiologic   study   of   young      Psychiatry  Res. 1991;37(1):11-23.
  18. Demiryurek BE, Ertem DH, Tekin A, Ceylan M, Aras YG, Gungen BD. Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine. Neurol Sci. 2016;37(11):1779-84.
  19. Miranda H, Ortiz G, Figueroa S, Pérez CM, Suárez E. Depression scores following migraine treatment in patients attending a specialized center for headache and neurology. Headache. 2001;41(7):680-4.
  20. Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology. 1999;53(5):988-94.
  21. Ghorbani A, Chitsaz A. Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population. Iran J Neurol. 2011;10(3-4):39-42.
  22. Ghassemzadeh H, Mojtabai R, Karamghadiri N, Ebrahimkhani N. Psychometric properties of a Persian language version of the Beck Depression Inventory—Second edition: BDI-II-PERSIAN. Depress Anxiety. 2005;21(4):185- 92.
  23. Cardona-Castrillon GP, Isaza R, Zapata-Soto AP, Franco JG, Gonzalez-Berrio C, Tamayo-Diaz CP. The comorbidity of major depressive disorder, dysthymic disorder and anxiety disorders with migraine. Rev Neurol. 2007;45(5):272-5.
  24. Domingues RB, Costa EA, Jr SA, Domingues SA, Leal JC, Gomez RS et al. Correlation between migraine subtypes and depression. Arq Neuropsiquiatr. 2008;66(3A):485-7.
  25. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain. 2012;13(8):615-24.
  26. Rammohan K, Mundayadan SM, Das S, Shaji CV. Migraine and mood disorders: prevalence, clinical correlations and disability. J Neurosci Rural Pract. 2019; 10(1): 28–33.
  27. Baldacci F, Lucchesi C, Cafalli M, Poletti M, Ulivi M, Vedovello M, et al. Migraine features in migraineurs with and without anxiety-depression symptoms: A hospital-based study. Clin Neurol Neurosurg. 2015;132:74–8.
  28. Bigal ME, Lipton RB. Clinical course in migraine: Conceptualizing migraine transformation. Neurology. 2008;71:848–55.
  29. Song TJ, Cho SJ, Kim WJ, Yang KI, Yun CH, Chu MK. Anxiety and depression in probable migraine: A population-based study. Cephalalgia 2017;37(9):845-54.
  30. Altamura C, Corbelli I, de Tommaso M, Di Lorenzo C, Di Lorenzo G, Di Renzo A, Filippi M, Jannini TB, Messina R, Parisi P, Parisi V, Pierelli F, Rainero I, Raucci U, Rubino E, Sarchielli P, Li L, Vernieri F, Vollono C, Coppola G. Pathophysiological bases of comorbidity in migraine. Front Hum Neurosci. 2021; 15: 640574.
  31. Chugani DC, Niimura K, Chaturversi S. Increased brain serotonin synthesis in migraine. Neurology. 1999;53(1):1473–83.
  32. Burstein R, Jakubowski M. Neural substrate of depression during migraine. Neurol Sci. 2009; 30(1):S27-31.
  33. Hornung JP. The human raphe nuclei and serotonergic system. J Chem Neuroanat. 2003;26(4):331-43.
  34. Pine DS, Cohen P, Brook J. The association between majo¨r depression and headache: reseults of a longitudinal epidemiologic study in youth. J Child Adolesc Psychopharmacol. 1996;6(1):153–64.
  35. Barbanti P, Fabbrini G, Ricci A, Pascali MP, Bronzetti E, Amenta F, et al. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia. 2000;20(1):15-9.
  36. Dresler T, Caratozzolo S, Guldolf K, Huhn JI, Loiacono C, Niiberg-Pikksööt T, Puma M, Sforza G, Tobia A, Ornello R, Serafini G, European Headache Federation School of Advanced Studies (EHF-SAS). Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implications. J Headache Pain. 2019;20(1):51.